\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Climate, Energy, MobilityThe 2023 demonstration project calls and the new hydrogen pilot auction for the Innovation Fund will both open on 23 November 2023. Together, the calls will make up to €4.8 billion available for industry and cleantech players in Europe to support the objectives of the European Green Deal and the Net-Zero Industry Act.
The hydrogen pilot auction will close on 8 February 2024 (estimated). Auctions are a new financing mechanism under the Innovation Fund and a key element of the EU Hydrogen Bank. A €800 million budget will be available for bidders (project developers). You can view the presentation and recording of DG CLIMA's info session on the pilot auction here.
The 2023 demonstration project calls will close on 9 April 2024 (estimated), with €4 billion budget for:
Flemish stakeholders can also find more information on the website of the Flemish Energy and Climate Agency (VEKA).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
